Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma

NCT01481870 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG: Sorafenib-sunitinib
DRUG: Sunitinib-sorafenib

Sponsor

Yamagata University